Myelofibrosis Market

[mistergern]

From Digital Report

Myelofibrosis Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Imago Biosciences, Actuate, Galecto, NS Pharma, Geron, iOnctura, Incyte Corporation, Keros Therapeutics, elgene/BMS, Sierra Oncology, AbbVie, Kartos Therapeutics, MorphoSys

PRESS RELEASE
Published March 21, 2023
Newsmantraa
Las Vegas (Nevada), United States //— The Myelofibrosis Market is set to register immense growth in the coming years owing to the extensive research and development activities of pharmaceutical companies in the therapeutics domain, the expected launch of approved therapies in the market, and the rise in the number of cases of Myelofibrosis in the 7MM.

Currently, some of the major pharma and biotech giants such as Geron (Imetelstat), AbbVie (Navitoclax), Sierra Oncology (Momelotinib), Incyte Corporation (Parsaclisib), Celgene/BMS (Luspatercept-aamt), MorphoSys (Pelabresib), Imago Biosciences (Bomedemstat), Pharmaxis (PXS-5505), and others are evaluating their lead candidates in different stages of clinical development.

Myelofibrosis: An Overview
Myelofibrosis (MF) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibres on which the stem cells can divide and grow. Specialised cells in the bone marrow known as fibroblasts make these fibres.

Mutations in the JAK2, MPL, CALR, and TET2 genes are associated with most cases of primary myelofibrosis. Primary myelofibrosis is most commonly diagnosed in people aged 50 to 80, but can occur at any age. Myelofibrosis can also progress to other, more aggressive, types of more aggressive forms.

Myelofibrosis Market Key Facts
– The United States accounts for the largest market size of Myelofibrosis USD 1,083 million, in comparison to EU4, the UK and Japan in 2021.
– Among EU4 countries, Germany had the highest market size, while Spain had the lowest market size of Myelofibrosis in 2021.
– The Japan Myelofibrosis market accounted for USD 74 million in 2021.
– The total prevalent population of myelofibrosis in the 7MM comprised 39,000+ cases in 2021 and is projected to increase during the study period (2019–2032).
– Among EU4 countries, Germany accounted for the highest number of myelofibrosis diagnosed prevalent cases, whereas Spain accounted for the lowest number of cases in 2021.
– The total prevalent cases of myelofibrosis in Japan was 5,391 in 2021 and is projected to increase during the forecast period.
– In 2021, the highest number of prevalent cases were observed in the US. The total prevalent population of myelofibrosis in the US is 19,815 in 2021 and is projected to increase during the forecast period (2022-2032).
– In various studies of European countries, the annual prevalence of MF ranged from 0.5–9 cases per 100,000 individuals.